Inactive Instrument

Speakeasy Cannabis Club Ltd.

EASY

CA84730M1023

Speakeasy Cannabis Club Ltd. Announces the Sudden Passing of Ian Waddell Q.C. Ian, Strategic Advisor to the Board

April 08, 2021 at 12:35 pm IST

Speakeasy Cannabis Club Ltd. announced the sudden passing of Ian Waddell Q.C. Ian who recently joined company's team as a strategic advisor to the board.

Latest news about Speakeasy Cannabis Club Ltd.

SpeakEasy Cannabis Club Ltd. Appoints Marc Geen as Corporate Secretary	22/22/22	CI
SpeakEasy Cannabis Club Ltd. Announces Chief Executive Officer Changes	22/22/22	CI
SpeakEasy Cannabis Club Ltd. Announces Executive Changes	22/22/22	CI
SpeakEasy Receives Licence for its 13,300 Sq Ft Craft Cannabis Flowering Facility, Tripling its Production Capabilities	14/22/14	CI
Speakeasy Cannabis Club Ltd. Announces the First Sale of Its Diamonds Infused Pre-Rolls	08/21/08	CI
SpeakEasy Cannabis Club Warns of Potential Delay in Filing Annual Results	26/21/26	MT
Speakeasy Cannabis Club Ltd. Announces Initiation of the 2021 Harvest With the Anticipation of a Bountiful Crop	07/21/07	CI
Speakeasy Cannabis Club : Disclosed Plan to Release Multiple Consumer Brands Over Next 12 Months; Falls 3.8% in Early Frankfurt Trading	23/21/23	MT
Speakeasy Cannabis Club : Health Canada Allows Speakeasy Cannabis to Sell Extract Products; Up Nearly 5% in Frankfurt Trading	02/21/02	MT
Speakeasy Receives Amendment to Its Sales Licence from Health Canada to Sell Extract Products	02/21/02	CI
Speakeasy Cannabis Club Ltd. cancelled the acquisition of Karolos Research Inc.	18/21/18	CI
Speakeasy Cannabis Club : Completes 2021 Planting Season, Provides Update on Harvest	10/21/10	MT
Speakeasy Cannabis Club : to Produce 2,225 kg of Extracts; Surges 15.4%	03/21/03	MT
\|SpeakEasy Cannabis Club Ltd. to Produce 2,225 kg of High Quality Extracts	01/21/01	CI
Speakeasy Cannabis Club Ltd. Reports Unaudited Consolidated Earnings Results for the Nine Months Ended April 30, 2021	02/21/02	CI
Speakeasy Cannabis Club Ltd Provides Updates on the Progress of Its Pre-Rolled Joints Production and Sales	27/21/27	CI
Speakeasy Cannabis Club Ltd. entered into a share purchase agreement to acquire Karolos Research Inc. for CAD 9.6 million.	24/21/24	CI
Update: Speakeasy Cannabis Up 5% as Targets 100% Yield Increase for 2021 Planting Season	18/21/18	MT
Speakeasy Cannabis Club : Targets 100% Yield Increase for 2021 Planting Season	18/21/18	MT
Speakeasy Cannabis Club Ltd. Announces Board Changes	07/21/07	CI
Speakeasy Cannabis Club Ltd. to Enter Psychedelics Sector with Narcotics Dealers Licence with A Focus on Psilocybin	06/21/06	CI
Speakeasy to Enter Psychedelics Sector with Narcotics Dealers Licence with A Focus on Psilocybin	06/21/06	CI
SpeakEasy Cannabis Club Ltd. Completes Product Menu for Two Upcoming Concentrate Brands	22/21/22	CI
Speakeasy Cannabis Club Ltd. announced that it has received CAD 3 million in funding	22/21/22	CI
Speakeasy Cannabis Club Ltd. Announces Entering Final Stage of Amended Sales Licensing for Extracts and Concentrates	13/21/13	CI

Chart Speakeasy Cannabis Club Ltd.

Duration

Period

More charts

SpeakEasy Cannabis Club Ltd. is a Canada-based cannabis company. The Company holds a cultivation, processing and sales license. The Company is engaged in producing cannabis and cannabis-derived extracts and derivatives for the Canadian market. It is a cannabis harvester in Canada producing from Western Canada's outdoor growing space. It cultivates small batch, craft cannabis at scale in a portion of its 63,200 square foot indoor cannabis complex and has completed its harvest of its 60-acre outdoor field. It owns approximately 290 acres of land in Rock Creek, British Columbia. The Company, through an extraction agreement with RC Frontier Labs Ltd, has completed its approximately 26,000 square foot processing and extraction facility. The Company's wholly owned subsidiary, 10161233 Canada Ltd, is a license holder for cultivation, processing and medical sales of cannabis.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+37.74%	723B
NOVO NORDISK A/S	+32.22%	598B
JOHNSON & JOHNSON	-2.07%	364B
MERCK & CO., INC.	+20.25%	331B
ABBVIE INC.	+2.99%	288B
ASTRAZENECA PLC	+16.60%	244B
NOVARTIS AG	+9.77%	210B
ROCHE HOLDING AG	-5.15%	208B
AMGEN INC.	+7.43%	169B

Other Pharmaceuticals